Core Insights - Cannara Biotech Inc. has achieved DTC eligibility for its common shares, enhancing trading liquidity and access for U.S. investors [1][2][3] - The company completed the issuance of 3,462,763 common shares to Olymbec Investments Inc. to settle approximately $6.2 million in debt, which includes $4.7 million in principal and $1.5 million in accrued interest [3][4] - The DTC eligibility is expected to broaden Cannara's shareholder base and increase visibility in the U.S. market, particularly in light of potential federal regulatory reforms in the cannabis industry [3][4] Company Overview - Cannara Biotech Inc. is a vertically integrated producer of premium-grade cannabis products, operating two mega facilities in Québec with a total area of over 1,650,000 sq. ft. [1][7] - The company has a potential annual cultivation output of 100,000 kg, leveraging low electricity costs in Québec to produce affordable cannabis products [7] Financial Strategy - The completion of the Olymbec share issuance is aimed at reducing debt leverage and interest obligations, thereby preserving liquidity for long-term growth strategies [4] - The transaction is anticipated to strengthen Cannara's balance sheet and enhance financial flexibility [4]

Core Viewpoint - Bitcoin Depot Inc. has announced a registered direct offering to sell 4,285,716 shares of its Class A common stock at a price of $3.50 per share, aiming to raise approximately $15 million in gross proceeds for general corporate purposes [1][2]. Group 1: Offering Details - The offering is expected to close on or about October 8, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. - The shares are being offered under a "shelf" registration statement filed with the SEC, which was declared effective on July 1, 2025 [3]. Group 2: Company Overview - Bitcoin Depot Inc. was founded in 2016 and operates as a Bitcoin ATM operator, providing users with a means to convert cash into Bitcoin [5]. - The company has a significant presence in North America, with over 9,000 kiosk locations as of August 2025, and operates in 47 states [5].

Board-certified medical oncologist joins AON’s CCBD physician teamBETHESDA, Md., Oct. 07, 2025 (GLOBE NEWSWIRE) -- American Oncology Network (AON), one of the nation’s fastest-growing networks of community-based oncology practices, and its partner practice, The Center for Cancer and Blood Disorders (CCBD), today announced that medical oncologist Chitra Rajagopal, MD (“Dr. Raj”), has joined the physician care team. She will see patients in Germantown and Bethesda, Maryland, alongside the practice’s existing ...

The accumulation to date has been supported by the partnership of Bitstamp by RobinhoodOMAHA, Neb., Oct. 07, 2025 (GLOBE NEWSWIRE) -- CleanCore Solutions, Inc. (NYSE American: ZONE) (“CleanCore” or the “Company”), today is providing an update on its Official Dogecoin Treasury (the “Treasury”), backed by the Dogecoin Foundation, and its new corporate arm House of Doge. Since launching the Treasury on September 5, 2025, CleanCore has executed a disciplined capital deployment approach, consistently purchasing ...

Seasoned Wealth Management Executive to Lead Growth and Retention StrategyISELIN, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Provident Bank, a leading New Jersey-based financial institution, has announced the appointment of Annamaria Vitelli as Executive Vice President, Chief Growth Officer of Beacon Trust, a full-service wealth management firm and wholly owned subsidiary of Provident Bank. In this newly created role, Ms. Vitelli will be responsible for overall growth and retention of client relationships acro ...

DALLAS, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Applied Digital Corporation (Nasdaq: APLD) ("Applied Digital" or the "Company"), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocations services for artificial intelligence, cloud, networking and blockchain workloads, announced today that it has received the initial funding from its previously disclosed perpetual preferred equity financing facility of up to $5.0 billion with Macquarie Asset Management (“MAM”). The ...

CHARLOTTE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- NN, Inc. (NASDAQ: NNBR), a global diversified industrial company that engineers and manufactures high-precision components and assemblies, announced today that senior management will be presenting virtually at the Noble Capital Markets Emerging Growth Virtual Equity Conference on Wednesday, October 8, 2025. The presentation will begin at 2:00 p.m. ET on Wednesday, October 8, 2025. Investors interested in accessing the webcast presentation may register to vi ...

Core Insights - VirTra, Inc. has received a $4.8 million multi-site award from the Bogotá Law Enforcement and Professional Division, part of the U.S. Department of State's Bureau of International Narcotics and Law Enforcement Affairs (INL), expected to be completed by mid-2026 [1][2] Group 1: Award Details - The award aims to enhance law enforcement training in Colombia, aligning with U.S. foreign assistance goals focused on police training and capacity building [2] - VirTra will provide seven four-screen V-ST PRO systems, along with Recoil Kits (RKs) and Advanced Skills Magazines (ASMs), to improve marksmanship training across various sites [3][4] Group 2: Technology and Training Capabilities - The V-ST PRO system features VirTra's proprietary V-Marksmanship program, allowing for diverse target training and scenarios that are challenging to replicate in traditional settings [3] - The simulator technology includes components that simulate reloads, malfunctions, and weapon handling skills, providing realistic training environments [4] Group 3: Company Growth and Future Prospects - The award signifies a milestone in VirTra's international growth and reflects the confidence global agencies have in its training technology [5] - The company recently announced full deployment with the Royal Canadian Mounted Police (RCMP) and is strengthening relationships with law enforcement agencies worldwide [5]

Core Insights - Galectin Therapeutics Inc. is participating in the AASLD Liver Meeting 2025, presenting data from the NAVIGATE trial on belapectin for MASH cirrhosis treatment [1][2] - The NAVIGATE trial data has been recognized for its significance in addressing the urgent need for therapies in MASH cirrhosis, highlighting belapectin's potential impact on treatment [2] Presentation Details - The oral presentation titled "Belapectin Reduces Liver Stiffness Progression and Prevents Varices at 18 Months in MASH Cirrhosis: Results from the NAVIGATE Trial" will take place on November 10, 2025 [3] - A poster presentation titled "Belapectin Maintains a Favorable Trend in Reducing Variceal Development Over 36 Months in MASH Cirrhosis: Results from the NAVIGATE Trial" is scheduled for November 8, 2025 [3] Company Overview - Galectin Therapeutics focuses on developing therapies for chronic liver disease and cancer, with belapectin as its lead drug targeting galectin-3 [4] - The company has received Fast Track designation from the FDA for belapectin, which is aimed at treating MASH with cirrhosis, a significant medical need [4] - Additional development programs include cancer immunotherapy, with the success of these programs dependent on finding suitable partnerships [4]

Core Insights - Bionano Genomics, Inc. will have its CEO, Erik Holmlin, participate in the H.C. Wainwright @ Home Event on October 15, 2025 [1][2] Company Overview - Bionano Genomics provides genome analysis solutions aimed at helping researchers and clinicians address complex biological and medical questions [3] - The company's mission is to revolutionize genome visualization through optical genome mapping (OGM) solutions, diagnostic services, and software [3] - Bionano offers OGM solutions applicable in basic, translational, and clinical research, along with a leading platform-agnostic genome analysis software and nucleic acid extraction solutions using proprietary isotachophoresis (ITP) technology [3] - Through its subsidiary, Lineagen, Inc. d/b/a Bionano Laboratories, the company provides OGM-based diagnostic testing services [3]